Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment

Aldo Bonaventura,Francesco Grossi,Federico Carbone,Alessandra Vecchié,Silvia Minetti,Nicholas Bardi,Edoardo Elia,Anna Maria Ansaldo,Daniele Ferrara,E. Rijavec,M.G. Dal Bello,Giovanni Rossi,Federica Biello,Marco Tagliamento,Angela Alama,Simona Coco,Paolo Spallarossa,Franco Dallegri,Carlo Genova,Fabrizio Montecucco

Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment

2020

Purpose Since the role of resistin was evaluated only in patients with non-small cell lung cancer (NSCLC) not treated with immunotherapy, we aimed to evaluate levels of resistin during immunotherapy (nivolumab) and its prognostic role with regard to OS.

Keywords:

Nivolumab
Medicine
Oncology
Resistin
non small cell
Pathology
Internal medicine
Lung cancer
Prospective cohort study
Gastroenterology
Myeloperoxidase
Immunotherapy
Cohort
Neutrophil degranulation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations